INTRODUCTION: Increased expression of cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT) may improve the antitumoral effect of 5-fluorouracil (5-FU) and 5-fluorocytosine (5-FC), and thereby enhance the potential of gene-directed enzyme prodrug therapy. For the applicability of gene-directed enzyme prodrug therapy in a clinical setting, it is essential to be able to monitor the transgene expression and function in vivo. Thus, we developed a preclinical tumor model to investigate the feasibility of using magnetic resonance spectroscopy and optical imaging to measure non-invasively CD and UPRT expression and function. MATERIALS AND METHODS: Expression vectors of CD or CD/UPRT fused to monomeric DsRed (mDsRed) were constructed and rat prostate carcinoma (R3327-AT) cell lines stably expressing either CD/mDsRed or CD/UPRT/mDsRed were generated. The expression of the fusion proteins was evaluated by flow cytometry, fluorescence microscopy, and Western blot analysis. The function of the fusion protein was confirmed in vitro by assessing 5-FC and 5-FU cytotoxicity. In vivo fluorine-19 magnetic resonance spectroscopy ((19)F MRS) was used to monitor the conversion of 5-FC to 5-FU in mice bearing the R3327-CD/mDsRed and R3327-CD/UPRT/mDsRed tumor xenografts. RESULTS: Sensitivity to 5-FC and 5-FU was higher in cells stably expressing the CD/UPRT/mDsRed fusion gene than in cells stably expressing CD/mDsRed alone or wild-type cells. Whole tumor (19)F MRS measurements showed rapid conversion of 5-FC to 5-FU within 20 min after 5-FC was administered intravenously in both CD/mDsRed and CD/UPRT/mDsRed tumors with subsequent anabolism to cytotoxic fluoronucleotides (FNucs). CD/UPRT/mDsRed tumor was more efficient in these processes. CONCLUSION: This study demonstrates the utility of these tumor models stably expressing CD or CD/UPRT to non-invasively evaluate the efficacy of the transgene expression/activity by monitoring drug metabolism in vivo using MRS, with potential applications in preclinical and clinical settings.
INTRODUCTION: Increased expression of cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT) may improve the antitumoral effect of 5-fluorouracil (5-FU) and 5-fluorocytosine (5-FC), and thereby enhance the potential of gene-directed enzyme prodrug therapy. For the applicability of gene-directed enzyme prodrug therapy in a clinical setting, it is essential to be able to monitor the transgene expression and function in vivo. Thus, we developed a preclinical tumor model to investigate the feasibility of using magnetic resonance spectroscopy and optical imaging to measure non-invasively CD and UPRTexpression and function. MATERIALS AND METHODS:Expression vectors of CD or CD/UPRT fused to monomeric DsRed (mDsRed) were constructed and ratprostate carcinoma (R3327-AT) cell lines stably expressing either CD/mDsRed or CD/UPRT/mDsRed were generated. The expression of the fusion proteins was evaluated by flow cytometry, fluorescence microscopy, and Western blot analysis. The function of the fusion protein was confirmed in vitro by assessing 5-FC and 5-FUcytotoxicity. In vivo fluorine-19 magnetic resonance spectroscopy ((19)F MRS) was used to monitor the conversion of 5-FC to 5-FU in mice bearing the R3327-CD/mDsRed and R3327-CD/UPRT/mDsRed tumor xenografts. RESULTS: Sensitivity to 5-FC and 5-FU was higher in cells stably expressing the CD/UPRT/mDsRed fusion gene than in cells stably expressing CD/mDsRed alone or wild-type cells. Whole tumor (19)F MRS measurements showed rapid conversion of 5-FC to 5-FU within 20 min after 5-FC was administered intravenously in both CD/mDsRed and CD/UPRT/mDsRed tumors with subsequent anabolism to cytotoxic fluoronucleotides (FNucs). CD/UPRT/mDsRed tumor was more efficient in these processes. CONCLUSION: This study demonstrates the utility of these tumor models stably expressing CD or CD/UPRT to non-invasively evaluate the efficacy of the transgene expression/activity by monitoring drug metabolism in vivo using MRS, with potential applications in preclinical and clinical settings.
Authors: Terence P F Gade; Jason A Koutcher; William M Spees; Bradley J Beattie; Vladimir Ponomarev; Michael Doubrovin; Ian M Buchanan; Tatiana Beresten; Kristen L Zakian; H Carl Le; William P Tong; Philipp Mayer-Kuckuk; Ronald G Blasberg; Juri G Gelovani Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701
Authors: R G Crystal; E Hirschowitz; M Lieberman; J Daly; E Kazam; C Henschke; D Yankelevitz; N Kemeny; R Silverstein; A Ohwada; T Russi; A Mastrangeli; A Sanders; J Cooke; B G Harvey Journal: Hum Gene Ther Date: 1997-05-20 Impact factor: 5.695
Authors: Manickam Muruganandham; Alan A Alfieri; Cornelia Matei; Yuchun Chen; George Sukenick; Isabel Schemainda; Max Hasmann; Leonard B Saltz; Jason A Koutcher Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: Fuqiu He; Ligeng Li; Dooha Kim; Bixiu Wen; Xuelong Deng; Philip H Gutin; Clifton C Ling; Gloria C Li Journal: Cancer Res Date: 2007-01-15 Impact factor: 12.701
Authors: Daniel Procissi; Filip Claus; Paul Burgman; Jacek Koziorowski; J Donald Chapman; Sunitha B Thakur; Cornelia Matei; C Clifton Ling; Jason A Koutcher Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: C E Badr; J M Niers; D Morse; J A Koelen; P Vandertop; D Noske; T Wurdinger; P A Zalloua; B A Tannous Journal: Gene Ther Date: 2010-12-09 Impact factor: 5.250
Authors: Marie-France Penet; Zhihang Chen; Cong Li; Paul T Winnard; Zaver M Bhujwalla Journal: Drug Deliv Transl Res Date: 2012-02-01 Impact factor: 4.617
Authors: L Xing; X Sun; X Deng; K Kotedia; P B Zanzonico; E Ackerstaff; J A Koutcher; C C Ling; G C Li Journal: Cancer Gene Ther Date: 2013-05-31 Impact factor: 5.987